[go: up one dir, main page]

HRP20130082A2 - Farmaceutski pripravak za produljeno oslobađanje trimetazidina - Google Patents

Farmaceutski pripravak za produljeno oslobađanje trimetazidina

Info

Publication number
HRP20130082A2
HRP20130082A2 HRP20130082AA HRP20130082A HRP20130082A2 HR P20130082 A2 HRP20130082 A2 HR P20130082A2 HR P20130082A A HRP20130082A A HR P20130082AA HR P20130082 A HRP20130082 A HR P20130082A HR P20130082 A2 HRP20130082 A2 HR P20130082A2
Authority
HR
Croatia
Prior art keywords
sustained release
trimetazidine
pharmaceutical composition
trimethazidine
agglomerant
Prior art date
Application number
HRP20130082AA
Other languages
English (en)
Inventor
Patrick Genty
Christophe Hermelin
Jean-Manuel Pean
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47504206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20130082(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of HRP20130082A2 publication Critical patent/HRP20130082A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pripravak za produljeno oslobađanje trimetazidina u kojem unutarnja faza sadrži trimetazidin, a vanjski sloj sadrži sredstvo za produljeno oslobađanje i antiaglomerant.
HRP20130082AA 2012-02-03 2013-01-30 Farmaceutski pripravak za produljeno oslobađanje trimetazidina HRP20130082A2 (hr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1200322A FR2986431B1 (fr) 2012-02-03 2012-02-03 Composition pharmaceutique a liberation prolongee de trimetazidine, son procede de fabrication et son utilisation dans des traitements therapeutiques

Publications (1)

Publication Number Publication Date
HRP20130082A2 true HRP20130082A2 (hr) 2013-08-31

Family

ID=47504206

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20130082AA HRP20130082A2 (hr) 2012-02-03 2013-01-30 Farmaceutski pripravak za produljeno oslobađanje trimetazidina
HRP20191072 HRP20191072T1 (hr) 2012-02-03 2019-06-14 Farmaceutski pripravak s produljenim otpuštanjem trimetazidina

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20191072 HRP20191072T1 (hr) 2012-02-03 2019-06-14 Farmaceutski pripravak s produljenim otpuštanjem trimetazidina

Country Status (47)

Country Link
US (1) US10117838B2 (hr)
EP (1) EP2623096B1 (hr)
JP (1) JP6338818B2 (hr)
KR (2) KR20130090365A (hr)
CN (2) CN106924221A (hr)
AP (1) AP2013006693A0 (hr)
AR (1) AR089861A1 (hr)
AU (1) AU2013200481B2 (hr)
BR (1) BR102013002524B1 (hr)
CA (1) CA2805471C (hr)
CL (1) CL2013000336A1 (hr)
CO (1) CO6720159A1 (hr)
CR (1) CR20130037A (hr)
CU (1) CU24157B1 (hr)
CY (1) CY1121696T1 (hr)
DK (1) DK2623096T3 (hr)
DO (1) DOP2013000024A (hr)
EA (1) EA030227B1 (hr)
EC (1) ECSP13012415A (hr)
ES (1) ES2735053T3 (hr)
FR (1) FR2986431B1 (hr)
GE (1) GEP20156342B (hr)
GT (1) GT201300032A (hr)
HR (2) HRP20130082A2 (hr)
HU (1) HUE043942T2 (hr)
IL (1) IL224495B (hr)
JO (1) JO3505B1 (hr)
LT (1) LT2623096T (hr)
MD (1) MD4622C1 (hr)
MX (1) MX363302B (hr)
MY (1) MY162599A (hr)
NI (1) NI201300014A (hr)
PE (1) PE20131119A1 (hr)
PH (1) PH12013000031B1 (hr)
PL (1) PL2623096T3 (hr)
PT (1) PT2623096T (hr)
RO (1) RO128004A3 (hr)
RS (2) RS20130034A1 (hr)
RU (1) RU2621128C2 (hr)
SG (1) SG192386A1 (hr)
SI (1) SI2623096T1 (hr)
SV (1) SV2013004396A (hr)
TR (1) TR201906390T4 (hr)
TW (1) TWI508755B (hr)
UA (1) UA118742C2 (hr)
UY (1) UY34595A (hr)
WO (1) WO2013114053A2 (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102322197B1 (ko) * 2014-04-08 2021-11-09 뉴트리션 & 바이오사이언시즈 유에스에이 1, 엘엘씨 에스테르화된 셀룰로오스 에테르를 포함하는 분산물
CA3044270A1 (en) * 2016-11-21 2018-05-24 Saghmos Therapeutics, Inc. The use of trimetazidine in the prevention and/or treatment of contrast-induced acute kidney injury____
CN109316455B (zh) * 2017-07-31 2021-05-25 北京福元医药股份有限公司 一种盐酸曲美他嗪缓释片
CN110237053A (zh) * 2019-07-26 2019-09-17 湖北欣泽霏药业有限公司 一种盐酸曲美他嗪缓释微丸及其制备方法
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법
WO2025068837A2 (en) * 2023-09-26 2025-04-03 Zim Laboratories Limited A novel extended release pharmaceutical composition of trimetazidine or salt thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122039C (hr) * 1960-10-20
FR2490963B1 (fr) 1980-09-30 1986-04-18 Science Union & Cie Nouvelle composition therapeutique a action anti-ischemique contenant de la trimethoxy 2, 3, 4-benzyl 1-piperazine
JPH04169522A (ja) * 1990-11-01 1992-06-17 Shin Etsu Chem Co Ltd 徐放性錠剤およびその製造方法
FR2717687B1 (fr) * 1994-03-24 1996-06-14 Adir Compositions pharmaceutiques permettant la libération prolongée de trimétazidine après administration par voie orale.
FR2802424B1 (fr) * 1999-12-17 2002-02-15 Adir Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
PT1195160E (pt) * 2000-10-05 2009-12-07 Usv Ltd Composições farmacêuticas de trimetazidina de libertação sustentada e método para a sua preparação
HUP0500382A3 (en) * 2001-11-21 2008-03-28 Themis Lab Private Ltd Sustained release pharmaceutical compositions containing microbeads of trimetazidine dihydrochloride and process for producing them
RU2281772C1 (ru) * 2005-02-14 2006-08-20 Закрытое акционерное общество "Фармацевтическое предприятие "Оболенское" Лекарственная форма, обладающая антиангинальным действием, и способ ее изготовления
EP2457562B1 (en) * 2006-05-09 2017-04-05 Mallinckrodt LLC Zero-order modified release solid dosage forms
CN100571703C (zh) * 2006-12-20 2009-12-23 山东省医药工业研究所 曲美他嗪缓释微丸及其制备方法
KR101122447B1 (ko) * 2007-11-09 2012-03-20 미쓰비시 타나베 파마 코퍼레이션 신규 제제
RU2362548C1 (ru) * 2007-11-20 2009-07-27 Закрытое Акционерное Общество "Канонфарма Продакшн" Матричная таблетка с основой для пролонгированного высвобождения триметазидина дигидрохлорида, способ ее получения и способ лечения
WO2010084397A2 (en) * 2009-01-20 2010-07-29 Micro Labs Limited Modified release solid pharmaceutical compositions of trimetazidine and process thereof
WO2010086868A1 (en) * 2009-01-30 2010-08-05 Lupin Limited Pharmaceutical compositions of trimetazidine
BRPI0924427A2 (pt) * 2009-03-18 2016-01-26 Evonik Roehm Gmbh composição farmacêutica de liberação controlada, seu processo de preparação e uso da mesma
ES2508490T3 (es) * 2010-05-04 2014-10-16 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Formulación de trimetazidina con diferentes perfiles de liberación
CN102133195A (zh) * 2011-03-17 2011-07-27 王国栋 盐酸曲美他嗪的缓控释微丸及其制备方法

Also Published As

Publication number Publication date
WO2013114053A2 (fr) 2013-08-08
PE20131119A1 (es) 2013-10-12
RO128004A0 (ro) 2012-12-28
GT201300032A (es) 2014-06-09
FR2986431B1 (fr) 2017-03-17
CU20130016A7 (es) 2014-10-02
CN103239425A (zh) 2013-08-14
RU2621128C2 (ru) 2017-05-31
PH12013000031A1 (en) 2014-09-22
AU2013200481B2 (en) 2015-01-22
RO128004A3 (ro) 2013-08-30
CA2805471C (fr) 2018-05-01
RS20130034A1 (en) 2013-10-31
EA030227B1 (ru) 2018-07-31
CA2805471A1 (fr) 2013-08-03
LT2623096T (lt) 2019-05-10
UY34595A (es) 2013-09-02
US10117838B2 (en) 2018-11-06
MY162599A (en) 2017-06-30
AP2013006693A0 (en) 2013-01-31
JP6338818B2 (ja) 2018-06-06
CN106924221A (zh) 2017-07-07
MX2013001118A (es) 2013-08-27
ES2735053T3 (es) 2019-12-13
BR102013002524B1 (pt) 2020-02-04
TW201332591A (zh) 2013-08-16
SG192386A1 (en) 2013-08-30
HRP20191072T1 (hr) 2019-11-01
MD4622C1 (ro) 2019-10-31
TWI508755B (zh) 2015-11-21
EA201300079A2 (ru) 2013-07-30
ECSP13012415A (es) 2014-09-30
MX363302B (es) 2019-03-20
WO2013114053A3 (fr) 2013-12-19
EP2623096A3 (fr) 2013-10-23
IL224495B (en) 2020-08-31
RS58752B1 (sr) 2019-06-28
CL2013000336A1 (es) 2014-07-18
EP2623096B1 (fr) 2019-04-03
EP2623096A2 (fr) 2013-08-07
CY1121696T1 (el) 2020-07-31
JO3505B1 (ar) 2020-07-05
PL2623096T3 (pl) 2019-08-30
UA118742C2 (uk) 2019-03-11
PH12013000031B1 (en) 2014-09-22
SV2013004396A (es) 2013-06-05
FR2986431A1 (fr) 2013-08-09
CU24157B1 (es) 2016-03-31
NI201300014A (es) 2013-05-13
DK2623096T3 (da) 2019-07-15
TR201906390T4 (tr) 2019-05-21
SI2623096T1 (sl) 2019-06-28
CO6720159A1 (es) 2013-07-31
GEP20156342B (en) 2015-08-10
NZ606550A (en) 2014-09-26
KR101918211B1 (ko) 2018-11-14
JP2013159609A (ja) 2013-08-19
AU2013200481A1 (en) 2013-08-22
MD20130005A2 (ro) 2013-07-31
BR102013002524A2 (pt) 2014-09-09
KR20150102922A (ko) 2015-09-09
AR089861A1 (es) 2014-09-24
MD4622B1 (ro) 2019-03-31
US20130202710A1 (en) 2013-08-08
DOP2013000024A (es) 2014-07-15
KR20130090365A (ko) 2013-08-13
HUE043942T2 (hu) 2019-09-30
CR20130037A (es) 2013-09-18
EA201300079A3 (ru) 2013-11-29
RU2013104252A (ru) 2014-08-10
PT2623096T (pt) 2019-05-30

Similar Documents

Publication Publication Date Title
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
BR112015002738A2 (pt) composto , e , composição farmacêutica
EP3021843A4 (en) Anti-viral compounds, pharmaceutical compositions, and methods of use thereof
BR112014030278A2 (pt) anticorpo, e, composição.
BR112014031262A2 (pt) composições biocatalisadoras inovadoras e processos para uso.
BR112015000420A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112015009718A2 (pt) composição de matéria e artigo.
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
BR112014031412A2 (pt) método de preparação de uma composição, composição e seu uso, e kit.
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
ZA201509307B (en) Pharmaceutical composition, preparation and uses thereof
EP3073171A4 (en) Heat-insulation film, and heat-insulation-film structure
CY1121696T1 (el) Φαρμακευτικη συνθεση παρατεταμενης απελευθερωσης της τριμεταζιδινης
CL2014003283A1 (es) Formulación farmacéutica.
EP2881444A4 (en) Water-repellent and oil-repellent composition and articles therewith
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
BR112014025416A2 (pt) AGENTES ANTIMALÁRICOS, COMPOSIÇÃO FARMACEUTICA COMPREENDENDO-OS E USO Dos MESMOS.
EP3037099A4 (en) Pharmaceutical composition, preparation method therefor and use thereof
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
BR112014032501A2 (pt) composto, e, composição farmacêutica.
BR112014027027A2 (pt) composição cosmética, método cosmético e uso de uma combinação.
EP3039009A4 (en) Mao-b selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof
BR112015009310A2 (pt) composição em pó, dose unitária da composição e uso não médico da composição ou da dose unitária.
BR112014020008A8 (pt) composição farmacêutica, uso da mesma, e, processo para a fabricação de uma formulação.
FR3012814B1 (fr) Composition polymere comprenant et liberant un compose actif odorant

Legal Events

Date Code Title Description
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
A1OB Publication of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20181210

Year of fee payment: 7

ODRP Renewal fee for the maintenance of a patent

Payment date: 20191212

Year of fee payment: 8

ODBI Application refused